163 related articles for article (PubMed ID: 16019715)
21. Impaired protection against diabetes and coronary heart disease by high-density lipoproteins in Turks.
Onat A; Can G; Ayhan E; Kaya Z; Hergenç G
Metabolism; 2009 Oct; 58(10):1393-9. PubMed ID: 19570555
[TBL] [Abstract][Full Text] [Related]
22. Increasing apoA-I production as a target for CHD risk reduction.
Dullens SP; Plat J; Mensink RP
Nutr Metab Cardiovasc Dis; 2007 Oct; 17(8):616-28. PubMed ID: 17703927
[TBL] [Abstract][Full Text] [Related]
23. Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis.
van Eijk IC; de Vries MK; Levels JH; Peters MJ; Huizer EE; Dijkmans BA; van der Horst-Bruinsma IE; Hazenberg BP; van de Stadt RJ; Wolbink GJ; Nurmohamed MT
Arthritis Rheum; 2009 May; 60(5):1324-30. PubMed ID: 19404933
[TBL] [Abstract][Full Text] [Related]
24. Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease.
Miller M; Ginsberg HN; Schaefer EJ
Am J Cardiol; 2008 Apr; 101(7):1003-8. PubMed ID: 18359322
[TBL] [Abstract][Full Text] [Related]
25. Current understanding of the role of high-density lipoproteins in atherosclerosis and senescence.
Nofer JR; Walter M; Assmann G
Expert Rev Cardiovasc Ther; 2005 Nov; 3(6):1071-86. PubMed ID: 16292998
[TBL] [Abstract][Full Text] [Related]
26. [Laboratory assessment of HDL heterogeneity and function].
Movva R; Rader DJ
Ann Biol Clin (Paris); 2009; 67(1):7-21. PubMed ID: 19189882
[TBL] [Abstract][Full Text] [Related]
27. High-density lipoprotein function recent advances.
Ansell BJ; Watson KE; Fogelman AM; Navab M; Fonarow GC
J Am Coll Cardiol; 2005 Nov; 46(10):1792-8. PubMed ID: 16286161
[TBL] [Abstract][Full Text] [Related]
28. Alcohol inflammation and coronary heart disease.
Imhof A; Koenig W
Addict Biol; 2003 Sep; 8(3):271-7. PubMed ID: 13129828
[TBL] [Abstract][Full Text] [Related]
29. Blockade of scavenger receptor class B type I raises high density lipoprotein cholesterol levels but exacerbates atherosclerotic lesion formation in apolipoprotein E deficient mice.
Kitayama K; Nishizawa T; Abe K; Wakabayashi K; Oda T; Inaba T; Amemiya Y
J Pharm Pharmacol; 2006 Dec; 58(12):1629-38. PubMed ID: 17331327
[TBL] [Abstract][Full Text] [Related]
30. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22.
Ray KK; Cannon CP; Cairns R; Morrow DA; Ridker PM; Braunwald E
Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):424-30. PubMed ID: 19122170
[TBL] [Abstract][Full Text] [Related]
31. [Vascular inflammation: effect of proatherogenic dyslipidemic trio or quartet].
Zamaklar M; Lalić K; Lalić N
Med Pregl; 2009; 62 Suppl 3():37-42. PubMed ID: 19702114
[TBL] [Abstract][Full Text] [Related]
32. [High density lipoproteins (HDL). A therapeutic objective in the atherosclerosis prevention?].
Pérez-Méndez O
Arch Cardiol Mex; 2004; 74(1):53-67. PubMed ID: 15125268
[TBL] [Abstract][Full Text] [Related]
33. Trimerization of apolipoprotein A-I retards plasma clearance and preserves antiatherosclerotic properties.
Graversen JH; Laurberg JM; Andersen MH; Falk E; Nieland J; Christensen J; Etzerodt M; Thøgersen HC; Moestrup SK
J Cardiovasc Pharmacol; 2008 Feb; 51(2):170-7. PubMed ID: 18287885
[TBL] [Abstract][Full Text] [Related]
34. AAV gene therapy as a means to increase apolipoprotein (Apo) A-I and high-density lipoprotein-cholesterol levels: correction of murine ApoA-I deficiency.
Vaessen SF; Veldman RJ; Comijn EM; Snapper J; Sierts JA; van den Oever K; Beattie SG; Twisk J; Kuivenhoven JA
J Gene Med; 2009 Aug; 11(8):697-707. PubMed ID: 19431216
[TBL] [Abstract][Full Text] [Related]
35. Apolipoprotein M likely extends its anti-atherogenesis via anti-inflammation.
Huang XS; Zhao SP; Hu M; Luo YP
Med Hypotheses; 2007; 69(1):136-40. PubMed ID: 17218068
[TBL] [Abstract][Full Text] [Related]
36. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA
Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582
[TBL] [Abstract][Full Text] [Related]
37. Apolipoprotein A-I mimetic peptides.
Navab M; Anantharamaiah GM; Reddy ST; Hama S; Hough G; Grijalva VR; Yu N; Ansell BJ; Datta G; Garber DW; Fogelman AM
Arterioscler Thromb Vasc Biol; 2005 Jul; 25(7):1325-31. PubMed ID: 15831812
[TBL] [Abstract][Full Text] [Related]
38. The dual nature of HDL: Anti-Inflammatory and pro-Inflammatory.
Namiri-Kalantari R; Gao F; Chattopadhyay A; Wheeler AA; Navab KD; Farias-Eisner R; Reddy ST
Biofactors; 2015 May; 41(3):153-9. PubMed ID: 26072738
[TBL] [Abstract][Full Text] [Related]
39. [High-density lipoproteins: the "new" target of cardiovascular medicine].
Sampietro T; Bigazzi F; Dal Pino B; Puntoni M; Bionda A
Ital Heart J Suppl; 2005 Jun; 6(6):341-53. PubMed ID: 16013425
[TBL] [Abstract][Full Text] [Related]
40. HDL: the 'new' target of cardiovascular medicine.
Sampietro T; Bigazzi F; Dal Pino B; Puntoni M; Bionda A
Int J Cardiol; 2006 Apr; 108(2):143-54. PubMed ID: 15978685
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
